Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q3 FY26 results · Oct–Dec 2025
Aarti Drugs reported revenue from operations of ₹601.71 crore (up 8.1% from Q3 FY25) and net profit of ₹40.55 crore (up 9.3% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 601.71 | 556.60 | +8.1% | 652.79 | −7.8% |
| Other income | 1.23 | 11.90 | −89.7% | 0.09 | 14x |
| Total income | 602.94 | 568.50 | +6.1% | 652.88 | −7.6% |
| Profit before tax | 29.02 | 50.76 | −42.8% | 60.41 | −52.0% |
| Net profit for the period | 40.55 | 37.09 | +9.3% | 45.16 | −10.2% |
| Attributable to shareholders of the company | 40.54 | 37.05 | +9.4% | 45.28 | −10.5% |
| EPS, basic (₹) | 4.44 | 4.06 | +9.4% | 4.95 | −10.3% |
| Net margin (%) | 6.7 | 6.7 | 6.9 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 528.80 | 514.54 | +2.8% | 578.95 | −8.7% |
| Other income | 1.22 | 11.37 | −89.3% | 0.15 | +713.3% |
| Total income | 530.02 | 525.91 | +0.8% | 579.10 | −8.5% |
| Profit before tax | 21.71 | 52.03 | −58.3% | 55.78 | −61.1% |
| Net profit for the period | 33.84 | 38.53 | −12.2% | 41.78 | −19.0% |
| EPS, basic (₹) | 3.71 | 4.22 | −12.1% | 4.58 | −19.0% |
| Net margin (%) | 6.4 | 7.5 | 7.2 |
Consolidated
- Filed with BSE
- 03 Feb 2026, 20:48 IST
- Board meeting
- 03 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 03 Feb 2026, 20:48 IST
- Board meeting
- 03 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Audited
- Source
- XBRL filing on BSE